{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T18:36:01Z","timestamp":1788978961826,"version":"build-2803163510"},"reference-count":45,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100008484","name":"BioMarin Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008484","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Endocrinology"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Hypochondroplasia is a skeletal dysplasia characterized by disproportionate short stature that is caused by gain-of-function variants in the fibroblast growth factor receptor 3 gene (\n                      <jats:italic toggle=\"yes\">FGFR3<\/jats:italic>\n                      ), which negatively regulates endochondral bone growth. Current treatments are based on symptom management; there are no treatments targeting the signaling pathways that underlie hypochondroplasia. Vosoritide, a C-type natriuretic peptide analog that counteracts overactive FGFR3 signaling to stimulate endochondral bone growth, is approved for the treatment of achondroplasia in children. A phase 1\/2 clinical trial demonstrated that vosoritide treatment for 1 year increased growth in children with hypochondroplasia and was well-tolerated.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>The objectives of CANOPY HCH-3 are to evaluate the efficacy and safety of vosoritide for the treatment of hypochondroplasia in children.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>CANOPY HCH-3 was a phase 3, randomized, double-blind, placebo-controlled, multicenter study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and Analysis<\/jats:title>\n                    <jats:p>Children aged \u22653 to &lt;18 years with confirmed hypochondroplasia who had \u22656 months of pre-treatment standing height from a prior observational study before randomization were enrolled. Participants were randomized to receive 52 weeks of daily treatment with vosoritide or placebo, followed by 2 weeks of safety follow-up. The primary endpoint is change from baseline in annualized growth velocity at week 52 versus placebo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics<\/jats:title>\n                    <jats:p>CANOPY HCH-3 was conducted in accordance with the Council for International Organizations of Medical Sciences International Ethical Guidelines, the principles of the Declaration of Helsinki and of Good Clinical Practice, and applicable laws and regulations. Protocols were approved by relevant local health authorities, ethics committees, and institutions. Written informed consent from the participant, or parent or legal guardian, was obtained prior to any study-related procedures being performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>CANOPY HCH-3 will provide further evidence for the efficacy and safety of vosoritide in children with hypochondroplasia.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/20420188261480984","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T11:02:26Z","timestamp":1788346946000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["A phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of vosoritide in children with hypochondroplasia: CANOPY HCH-3 study design"],"prefix":"10.1177","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4890-0262","authenticated-orcid":false,"given":"Andrew","family":"Dauber","sequence":"first","affiliation":[{"name":"Children\u2019s National Hospital"},{"name":"The George Washington University School of Medicine and Health Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Savarirayan","sequence":"additional","affiliation":[{"name":"Murdoch Children\u2019s Research Institute"},{"name":"Genetics Services, The Royal Children\u2019s Hospital Melbourne"},{"name":"The University of Melbourne"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricki","family":"Carroll","sequence":"additional","affiliation":[{"name":"Nemours Children\u2019s Hospital Delaware"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moira","family":"Cheung","sequence":"additional","affiliation":[{"name":"NIHR Great Ormond Street Hospital Biomedical Research Centre"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2839-9856","authenticated-orcid":false,"given":"Val\u00e9rie","family":"Cormier-Daire","sequence":"additional","affiliation":[{"name":"Necker-Enfants Malades Hospitals"},{"name":"Paris Cit\u00e9 University"},{"name":"Inserm UMR1163"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Maghnie","sequence":"additional","affiliation":[{"name":"IRCCS Istituto Giannina Gaslini"},{"name":"University of Genoa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriyuki","family":"Namba","sequence":"additional","affiliation":[{"name":"Tottori University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Semler","sequence":"additional","affiliation":[{"name":"University of Cologne"},{"name":"University Hospital Cologne"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sajda","family":"Ghani","sequence":"additional","affiliation":[{"name":"BioMarin Europe Ltd"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Sabir","sequence":"additional","affiliation":[{"name":"BioMarin Europe Ltd"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Bassi","sequence":"additional","affiliation":[{"name":"BioMarin Pharmaceutical Inc"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,9,2]]},"reference":[{"key":"e_1_3_8_2_2","volume-title":"GeneReviews\u00ae [Internet]","author":"Bober MB","year":"1993","unstructured":"Bober MB, Bellus GA, Cheung MS, et al. Hypochondroplasia. In: Adam MP, Bick S, Mirzaa GM, et al. (eds). GeneReviews\u00ae [Internet]. University of Washington, Seattle, 1993-2025. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1477\/ accessed 3 December 2025."},{"key":"e_1_3_8_3_2","unstructured":"Mukherjee S Reddy SR Pimenta JM et al. Medical impact of hypochondroplasia among children and adults in England: a 22-year retrospective study. Poster presented at: Pediatric Endocrine Society. National Harbor 2025. Poster 42."},{"key":"e_1_3_8_4_2","doi-asserted-by":"publisher","DOI":"10.1136\/jmg.26.1.37"},{"key":"e_1_3_8_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.35327"},{"key":"e_1_3_8_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.63431"},{"key":"e_1_3_8_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.35642"},{"key":"e_1_3_8_8_2","doi-asserted-by":"publisher","DOI":"10.1159\/000545318"},{"key":"e_1_3_8_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/mgg3.70151"},{"key":"e_1_3_8_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2012.10.014"},{"key":"e_1_3_8_11_2","doi-asserted-by":"publisher","DOI":"10.1159\/000520812"},{"key":"e_1_3_8_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/ng0795-357"},{"key":"e_1_3_8_13_2","doi-asserted-by":"publisher","DOI":"10.1136\/jmg.33.9.749"},{"key":"e_1_3_8_14_2","volume-title":"Report on investigation results: somatropin","author":"Pharmaceuticals and Medical Devices Agency (Japan)","year":"2022","unstructured":"Pharmaceuticals and Medical Devices Agency (Japan). Report on investigation results: somatropin, 2022. https:\/\/www.pmda.go.jp\/files\/000246397.pdf accessed 12 May 2026."},{"key":"e_1_3_8_15_2","unstructured":"BioMarin Pharmaceutical Inc. Data on file."},{"key":"e_1_3_8_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.yapd.2022.03.005"},{"key":"e_1_3_8_17_2","volume-title":"Assessment report for Somatropin-containing medicinal products","author":"European Medicines Agency","year":"2012","unstructured":"European Medicines Agency. Assessment report for Somatropin-containing medicinal products, 2012. https:\/\/www.ema.europa.eu\/en\/documents\/referral\/somatropin-article-107-referral-assessment-report_en.pdf, accessed 7 May 2026."},{"key":"e_1_3_8_18_2","doi-asserted-by":"publisher","DOI":"10.2217\/pgs.15.129"},{"key":"e_1_3_8_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-024-01074-9"},{"key":"e_1_3_8_20_2","first-page":"238","article-title":"Limb lengthening in short stature patients","volume":"10","author":"Aldegheri R","year":"2001","unstructured":"Aldegheri R, Dall'Oca C. Limb lengthening in short stature patients. J Pediatr Orthop B 2001; 10: 238\u2013247.","journal-title":"J Pediatr Orthop B"},{"key":"e_1_3_8_21_2","doi-asserted-by":"publisher","DOI":"10.1186\/s10195-019-0541-3"},{"key":"e_1_3_8_22_2","first-page":"540","article-title":"Extensive limb lengthening for achondroplasia and hypochondroplasia","volume":"8","author":"Paley D","year":"2021","unstructured":"Paley D. Extensive limb lengthening for achondroplasia and hypochondroplasia. Children (Basel) 2021; 8: 540. https:\/\/doi.org\/10.3390\/children8070540","journal-title":"Children (Basel)"},{"key":"e_1_3_8_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31541-5"},{"key":"e_1_3_8_24_2","volume-title":"FDA approves first drug to improve growth in children with most common form of dwarfism","author":"US Food and Drug Administration","year":"2021","unstructured":"US Food and Drug Administration. FDA approves first drug to improve growth in children with most common form of dwarfism, 2021. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-drug-improve-growth-children-most-common-form-dwarfism accessed 12 February 2026."},{"key":"e_1_3_8_25_2","volume-title":"Voxzogo","author":"European Medicines Agency","year":"2025","unstructured":"European Medicines Agency. Voxzogo, 2025. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/voxzogo accessed 12 February 2026."},{"key":"e_1_3_8_26_2","volume-title":"List of approved drugs April 2004 to June 2025","year":"2025","unstructured":"Pharmaceuticals and Medical Devices Agency (Japan). In: List of approved drugs April 2004 to June 2025, 2025. https:\/\/www.pmda.go.jp\/files\/000278243.pdf accessed 12 February 2026."},{"key":"e_1_3_8_27_2","volume-title":"Voxzogo (vosoritida): new record","author":"National Health Surveillance Agency (Brazil)","year":"2021","unstructured":"National Health Surveillance Agency (Brazil). Voxzogo (vosoritida): new record, 2021. https:\/\/www.gov.br\/anvisa\/pt-br\/assuntos\/medicamentos\/novos-medicamentos-e-indicacoes\/voxzogo-vosoritida-novo-registro accessed 12 February 2026."},{"key":"e_1_3_8_28_2","volume-title":"Voxzogo","author":"Therapeutic Goods Administration (Australia)","year":"2022","unstructured":"Therapeutic Goods Administration (Australia). Voxzogo, 2022. https:\/\/www.tga.gov.au\/resources\/auspmd\/voxzogo accessed 12 February 2026."},{"key":"e_1_3_8_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102591"},{"key":"e_1_3_8_30_2","volume-title":"Interventional study of vosoritide for the treatment of children with hypochondroplasia (CANOPY-HCH-3)","author":"ClinicalTrials.gov","year":"2026","unstructured":"ClinicalTrials.gov. Interventional study of vosoritide for the treatment of children with hypochondroplasia (CANOPY-HCH-3), 2026. https:\/\/clinicaltrials.gov\/study\/NCT06455059 accessed 12 February 2026."},{"key":"e_1_3_8_31_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2024-081477"},{"key":"e_1_3_8_32_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2024-081660"},{"key":"e_1_3_8_33_2","volume-title":"A multicenter multinational observational study of children with hypochondroplasia","author":"ClinicalTrials.gov","year":"2025","unstructured":"ClinicalTrials.gov. A multicenter multinational observational study of children with hypochondroplasia, 2025. https:\/\/clinicaltrials.gov\/study\/NCT06212947 accessed 12 February 2026."},{"key":"e_1_3_8_34_2","volume-title":"Long-term extension study of vosoritide to treat children with hypochondroplasia (CANOPY-HCH-EXT)","author":"ClinicalTrials.gov","year":"2025","unstructured":"ClinicalTrials.gov. Long-term extension study of vosoritide to treat children with hypochondroplasia (CANOPY-HCH-EXT), 2025. https:\/\/clinicaltrials.gov\/study\/NCT07073014 accessed 12 November 2025."},{"key":"e_1_3_8_35_2","volume-title":"A study to evaluate the efficacy and safety of BMN 111 in children with achondroplasia","author":"ClinicalTrials.gov","year":"2022","unstructured":"ClinicalTrials.gov. A study to evaluate the efficacy and safety of BMN 111 in children with achondroplasia, 2022. https:\/\/clinicaltrials.gov\/study\/NCT03197766 accessed 4 June 2026."},{"key":"e_1_3_8_36_2","volume-title":"VOXOGO\u00ae (vosoritide) (Prescribing Information)","author":"BioMarin Pharmaceutical Inc","year":"2024","unstructured":"BioMarin Pharmaceutical Inc. VOXOGO\u00ae (vosoritide) (Prescribing Information). BioMarin Pharmaceutical Inc, 2024."},{"key":"e_1_3_8_37_2","volume-title":"Achondroplasia, BioMarin; list results","author":"ClinicalTrials.gov","year":"2026","unstructured":"ClinicalTrials.gov. Achondroplasia, BioMarin; list results, 2026. https:\/\/www.clinicaltrials.gov\/search?cond=Achondroplasia&term=BioMarin-Pharmaceutical&viewType=Table&limit=25&page=1 accessed 12 February 2026."},{"key":"e_1_3_8_38_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1813446"},{"key":"e_1_3_8_39_2","unstructured":"Ziv N Jeong R Carus Sahin YO et al. Comprehensive analysis of FGFR3 variants identified >10 candidate hypochondroplasia variants with potential to increase diagnostic yield. In: Poster presented at: American Society for Bone and Mineral Research 2025 (ASBMR) Annual Meeting Seattle WA USA: 5-8 September 2025 Poster #Fri-506."},{"key":"e_1_3_8_40_2","volume-title":"StatPearls [Internet]","author":"Chamarthi VS","year":"2025","unstructured":"Chamarthi VS, Chamarthi S, Karsonovich T. Achondroplasia. In: StatPearls [Internet]. StatPearls Publishing, 2025. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK559263\/ accessed 5 May 2026."},{"key":"e_1_3_8_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ydbio.2004.11.035"},{"key":"e_1_3_8_42_2","volume-title":"214938Orig1s000 Integrated Review","author":"Center for Drug Evaluation and Research","year":"2021","unstructured":"Center for Drug Evaluation and Research. 214938Orig1s000 Integrated Review, 2021. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2021\/214938Orig1s000IntegratedR.pdf, accessed 6 May 2026."},{"key":"e_1_3_8_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.gim.2024.101274"},{"key":"e_1_3_8_44_2","first-page":"43","article-title":"Evaluation of short and tall stature in children","volume":"92","author":"Barstow C","year":"2015","unstructured":"Barstow C, Rerucha C. Evaluation of short and tall stature in children. Am Fam Physician 2015; 92: 43\u201350.","journal-title":"Am Fam Physician"},{"key":"e_1_3_8_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.gim.2022.08.015"},{"key":"e_1_3_8_46_2","volume-title":"An interventional study of infigratinib in children with hypochondroplasia (HCH)","author":"ClinicalTrials.gov","year":"2025","unstructured":"ClinicalTrials.gov. An interventional study of infigratinib in children with hypochondroplasia (HCH), 2025. https:\/\/clinicaltrials.gov\/study\/NCT06873035 accessed 19 December 2025."}],"container-title":["Therapeutic Advances in Endocrinology and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20420188261480984","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20420188261480984","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20420188261480984","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T03:46:31Z","timestamp":1788579991000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/20420188261480984"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":45,"alternative-id":["10.1177\/20420188261480984"],"URL":"https:\/\/doi.org\/10.1177\/20420188261480984","relation":{},"ISSN":["2042-0188","2042-0196"],"issn-type":[{"value":"2042-0188","type":"print"},{"value":"2042-0196","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]},"article-number":"20420188261480984"}}